Ex vivo tissue modelling informs drug selection for rare cancers.

Abstract excerpt

The identification and therapeutic targeting of actionable gene mutations across many cancer types has resulted in improved response rates in a minority of patients. The identification of actionable mutations is usually not sufficient to ensure complete nor durable responses, and in rare cancers, where no therapeutic standard of care exists, precision medicine indications are often based on pan-cancer data. The...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Thyroid Neoplasms
• Share to Mutation